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Introduction: Secondary hyperparathyroidism is highly prevalent in kidney transplant recip-
ients, and commonly results in hypercalcaemia; an association to osteopenia and bone
fractures has also been observed. Paricalcitol has proved effective to control secondary
hyperparathyroidism in chronic kidney disease in both dialysed and non-dialysed patients,
with a low hypercalcaemia incidence. Currently available experience on paricalcitol use in
kidney transplant recipients is scarce. Our main aim was to show the effect of paricalcitol
on  mineral bone metabolism in kidney transplant recipients with secondary hyperparathy-
roidism.
Material and methods: A retrospective multicentre study in kidney transplant recipients aged
>18 years with a 12-month or longer post-transplantation course, stable renal function,
having received paricalcitol for more than 12 months, with available clinical follow-up for a
24-month period.
Results: A total of 69 patients with a 120 ± 92-month post-transplantation course
were  included. Baseline creatinine was 2.2 ± 0.9 mg/dL and GFR-MDRD was
36  ± 20 mL/min/1.73 m2. Paricalcitol doses were gradually increased during the study:
baseline 3.8 ± 1.9 g/week, 12 months 5.2 ± 2.4 g/week; 24 months 6.0 ± 2.9 g/week
(P  < .001). Serum PTH levels showed a signiﬁcant fast decline: baseline 288 ± 152 pg/mL;
6  months 226 ± 184 pg/mL; 12 months 207 ± 120; 24 months 193 ± 119 pg/mL (P < .001).
Reduction from baseline PTH was ≥30% in 42.4% of patients at 12 months and in 65.2% of
patients at 24 months. Alkaline phosphatase showed a signiﬁcant decrease in ﬁrst 6 months
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followed by a plateau: baseline 92 ± 50 IU/L; 6 months 85 ± 36 IU/L, 12 months 81 ± 39 IU/L
(P  < .001). Overall, no changes were observed in serum calcium and phosphorus, and in urine
calcium excretion. PTH decline was larger in patients with higher baseline levels. Patients
with  lower baseline calcium levels showed signiﬁcantly increased levels (mean increase
was  0.5–0.6 mg/dL) but still within normal range, whereas patients with baseline calcium
>10  mg/dL showed gradually decreasing levels. Fifteen (21.7%) patients had received prior
calcitriol therapy. When shifted to paricalcitol, such patients required paricalcitol doses
signiﬁcantly larger than those not having received calcitriol. Paricalcitol was used concomi-
tantly to cinacalcet in 11 patients with signiﬁcant PTH reductions being achieved; clinical
course was similar to other patients and paricalcitol doses were also similar.
Conclusions: Paricalcitol is an effective therapy for secondary hyperparathyroidism in kidney
transplant recipients. Overall, no signiﬁcant changes were observed in calcium and phos-
phorus levels or urinary excretion. Patients having previously received calcitriol required
higher paricalcitol doses. When used in patients receiving cinacalcet, paricalcitol results
in  a signiﬁcant PTH fall, with paricalcitol doses being similar to those used in patients not
receiving cinacalcet.
© 2015 Sociedad Espan˜ola de Nefrología. Published by Elsevier España, S.L.U. This is an
open  access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
Efecto  de  paricalcitol  sobre  el  metabolismo  mineralóseo  en  pacientes
trasplantados  renales  con  hiperparatiroidismo  secundario
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Calcitriol
r  e  s  u  m  e  n
Introducción: El hiperparatiroidismo secundario es muy prevalente en pacientes trasplan-
tados renales. Cursa con frecuencia con hipercalcemia y se ha asociado al desarrollo de
osteopenia y fracturas óseas. El paricalcitol ha mostrado su eﬁcacia en el control del hiper-
paratiroidismo secundario en la enfermedad renal crónica con y sin diálisis, con una baja
incidencia de hipercalcemia. La experiencia con paricalcitol en trasplantados renales es muy
escasa. El objetivo de este trabajo fue mostrar el efecto sobre el metabolismo mineralóseo
del  paricalcitol en trasplantados renales con hiperparatiroidismo secundario.
Material y métodos: Estudio retrospectivo multicéntrico con trasplantados renales de más de
18  an˜os de edad y más de 12 meses de evolución postrasplante, con función renal estable,
que  hayan sido tratados con paricalcitol durante más de 12 meses, con seguimiento clínico
hasta los 24 meses de tratamiento.
Resultados: Se incluyó a 69 pacientes, con 120 ± 92 meses postrasplante, con creatin-
ina  inicial de 2,2 ± 0,9 mg/dl y FG-MDRD 36 ± 20 ml/min/1,73 m2. La dosis de paricalcitol
se  incrementó progresivamente durante el estudio: basal 3,8 ± 1,9 g/semana, 12 meses
5,2  ± 2,4 g/semana; 24 meses 6,0 ± 2,9 g/semana (p < 0,001). Los niveles séricos de PTH
descendieron de forma rápida y signiﬁcativa: basal 288 ± 152 pg/ml; 6 meses 226 ± 184 pg/ml;
12  meses 207 ± 120; 24 meses 193 ± 119 pg/ml (p < 0,001). Observamos una reducción sobre
PTH basal ≥30% en el 42,4% de los pacientes a los 12 meses y en el 65,2% de los pacientes a
los  24 meses. La fosfatasa alcalina descendió también signiﬁcativamente en los 6 primeros
meses para luego estabilizarse: basal 92 ± 50 UI/l; 6 meses 85 ± 36 UI/l, 12 meses 81 ± 39
UI/l  (p < 0,001). Globalmente no hubo modiﬁcaciones en el calcio o fósforo séricos ni en la
excreción urinaria de calcio. La reducción de PTH fue más importante en trasplantados con
niveles séricos más elevados de partida. Observamos que los pacientes con calcio basal
más  bajo mostraron un incremento signiﬁcativo de sus cifras de 0,5-0,6 mg/dl en prome-
dio  aunque manteniéndose en rango de normalidad, mientras que pacientes con calcio
basal > 10 mg/dl mostraron una reducción progresiva de sus cifras. Quince (21,7%) pacientes
seguían tratamiento previo con calcitriol y al cambiarlos a paricalcitol precisaron dosis signi-
ﬁcativamente mayores que los pacientes que no habían recibido calcitriol. El paricalcitol fue
asociado a cinacalcet en 11 pacientes, con reducciones signiﬁcativas de PTH, con evolución
similar al resto de la población y con dosis de paricalcitol también similares.
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Conclusiones: Paricalcitol es eﬁcaz en el tratamiento del hiperparatiroidismo secundario
de trasplantados renales. Globalmente no observamos modiﬁcaciones signiﬁcativas
de los niveles de calcio ni de fósforo, ni en su excreción urinaria. Los pacientes en
tratamiento previo con calcitriol precisaron dosis mayores de paricalcitol. Cuando el
paricalcitol se administra a pacientes tratados con cinacalcet, se observa un descenso
signiﬁcativo de la PTH con dosis de paricalcitol similar a pacientes sin cinacalcet.
© 2015 Sociedad Espan˜ola de Nefrología. Publicado por Elsevier España, S.L.U. Este es
ccess bajo la licencia CC BY-NC-ND (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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aricalcitol is a selective vitamin D receptor activator that
as been demonstrated to be effective in the treatment
f secondary hyperparathyroidism in advanced chronic kid-
ey disease1–3 and in dialysis patients.4,5 In haemodialysis
atients, paricalcitol has been shown to reduce serum
arathyroid hormone (PTH) levels by more  than 30% from
aseline in 68–91% of cases, by more  than 50% from baseline
n 45–60% of patients,2,4,6 and to reach levels recommended
n guidelines in 30–50% of patients. Some studies have
hown paricalcitol to be as effective or more  effective than
inacalcet.6 When paricalcitol was compared with calcitriol
n patients on haemodialysis with resistant hyperparathy-
oidism, reductions in PTH were observed, even in those
atients they did not respond to calcitriol.5–7 As compared
ith calcitriol, paricalcitol has less effect on calcium and phos-
horus transporter proteins at an intestinal level, therefore the
egree of increase in serum levels of calcium and phosphate is
ess after paricalcitol than calcitriol.8,9 This allows safer man-
gement in cases of more  severe hyperparathyroidism.
Residual hyperparathyroidism is common in renal trans-
lant recipients: various series have found that 30–50% of
atients have abnormal PTH levels.10,11 It is particularly
ommon to observe hypercalcaemia during the ﬁrst year post-
ransplant and in up to 10–40% of patients after more  than
ne year post-transplant.10,12 This may generate difﬁculties
n the treatment of residual hyperparathyroidism with vita-
in  D derivatives, such as calcitriol. Paricalcitol could have a
lear indication in the control of residual hyperparathyroidism
n renal transplant recipients, aiming for a more ambitious
eduction in PTH levels than what is often achieved in daily
linical practice.
There is little information about the use of paricalcitol in
enal transplant patients. In one randomised trial in renal
ransplant recipients receiving paricalcitol from the third day
ost-transplant, prevalence of residual hyperparathyroidism
t the end of the ﬁrst year was reduced to 29%, compared
ith 63% in the control group.13 In one retrospective study
n long-term transplant recipients, paricalcitol was shown
o reduce serum PTH levels and to have a low incidence of
ypercalcaemia.14The aim of this multi-hospital study was to retrospectively
ollect information on the effect of paricalcitol on bone min-
ral metabolism in long-term transplant recipients, analysingthe possible factors affecting changes in serum calcium and
PTH levels.
Patients  and  methods
This was a retrospective multicentre study with a single
cohort of renal transplant recipients. Inclusion criteria were:
renal transplant patients >18 years old, patients more  than
12 months post-transplant, stable renal function, and treat-
ment with paricalcitol for at least 12 months prior to the
year 2012. We chose a population with more than 12 months
post-transplant because during the ﬁrst year, the progres-
sive improvement in renal function or its deterioration due
to rejection or other causes may cause changes in PTH levels.
Such changes would add difﬁculties to a correct interpretation
to the direct potential effect of paricalcitol on PTH. In addition,
the administration of cinacalcet to control hypercalcemia is
more common during the ﬁrst year after transplantation; this
treatment may also have affected the results.
All participating centres were asked to provide information
on all patients who had received treatment with paricalcitol
and who met  the inclusion criteria. In each medical centre,
patients received treatment with paricalcitol for secondary
hyperparathyroidism in accordance with the standard clinical
practice protocol, either as a primary medication, as a substi-
tute for calcitriol treatment, or in conjunction with cinacalcet
treatment. Paricalcitol was prescribed initially at a dose of
2–3 g per week in most cases, with a progressive increase
in the dose to achieve the desired control of PTH. In patients
previously treated from calcitriol to paricalcitol, the dose con-
version ratio was lower than the recommended 4:1.
We gathered analytical data and dose of paricalcitol used
at baseline and at 6 month intervals during a 2 year of follow-
up period. Information was collected on whether patients had
received previous treatment with paricalcitol, and the dose
they had been taking. Patients on treatment with cinacal-
cet continued taking it, and the dose used at each stage
was noted. Parathyroid hormone was measured as intact PTH
using Roche® Elecsys electrochemiluminescence in all cen-
tres, therefore values did not require conversion (normal range
15–65 pg/mL). Our main objective was to collect and showdecreasing trends in their values, with means, standard devi-
ations, and standard errors (in graphs). Therefore, data are not
shown for individual cases of, for example, hypercalcaemia, as
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these cases were managed at the discretion of each nephrol-
ogist. Serum calcium levels were not corrected for albumin
because it was not available at all assessment times. Renal
function was represented by serum creatinine values and by
estimated glomerular ﬁltration rate using the MDRD4 equa-
tion (GFR-MDRD).
Statistical analysis was performed with the statistical pro-
gram SPSS 11.5. All continuous quantitative variables were
assessed for distribution; if they did not follow a normal
distribution, the variable was transformed using its natural
logarithm. This occurred for PTH and alkaline phosphatase.
Quantitative variables are expressed as mean and standard
deviation, except in the graphs, which show the mean and
standard error. Unpaired means of quantitative variables from
two groups were compared using the Mann–Whitney test and
the Friedman test when there were more  than 2 groups. Paired
means of 2 variables were compared using the Wilcoxon test.
Paired means of more  than 2 time points were compared using
repeated measures ANOVA, either directly or after logarithmic
transformation if they did not follow a normal distribution. For
analysis of subpopulations of interest, we  divided the popu-
lation into tertiles, avoiding individual values that could have
biased the results and with equal numbers in each stratum
studied. For multivariate analysis, we  used a linear regres-
sion analysis, checking if the remainders obtained followed a
normal distribution in the model constructed. For correlation
analysis, the Spearman coefﬁcient was whenever variables did
not follow a normal distribution. A P value <.05 was considered
statistically signiﬁcant.
Results
The epidemiological characteristics of the patients included in
the study are shown in Table 1. Most patients were long-term
renal transplant recipients: 84.1% of patients were more  than
2 years post-transplant and 63.8% of patients were more  than
5 years post-transplant. The distribution of cases by trans-
plant follow-up centre were: Cádiz, 3 cases; Granada, 24 cases;
Huelva, 11 cases; Jaen, 21 cases; Malaga, 4 cases; and Seville,
Table 1 – Epidemiological characteristics of the study
population.
N 69
Age 55 ± 12
Sex, M/F 34/35
Months post-transplant 120 ± 92 (median 100)
Weight, kg 75.2 ± 17.5
BMI, kg/m2 28.6 ± 6.2
SBP, mmHg 134 ± 18
DBP, mmHg 76 ± 11
Diabetes mellitus n (%) 14 (20.2)
Immunosuppression %
Ciclosporin A 29.0
Tacrolimus 55.1
Sirolimus 5.8
Everolimus 5.8
MMF/MPS 84.1
Azathioprine 7.2
Prednisone 91.3;3 5(4):363–373
6 cases. Age and post-transplant follow-up time were similar
for both sexes.
Initial PTH levels in the study population were as fol-
lows: PTH < 150 pg/mL, 17.2% of patients; PTH 150–249 pg/mL,
26.6%; PTH 250–349 pg/mL, 31.2%; PTH 350–500 pg/mL, 18.8%;
and PTH > 500 pg/mL, 6.2%. The prescribed starting dose of
paricalcitol was 3.7 ± 1.9 g/week, median 3 g/week, and
range 1–10 g/week. A dose lower than 3 g/week was pre-
scribed in 16 patients (23.2%); 3 g/week was prescribed in 30
patients (43.5%); 4–6 g/week was prescribed in 11 patients
(15.9%); 7 g/week was prescribed in 11 patients (15.9%);
and 10 g/week was prescribed in 1 patient. The PTH/dose
ratio was 88 ± 58 pg/mL/g/week (median 77 pg/mL/g/week).
Serum calcium was >10.5 mg/dL before starting treatment
with paricalcitol in seven patients (10.1%). Three of those
patients had had previous treatment with calcitriol, and one
with cinacalcet.
Paricalcitol dose was increased progressively throughout
follow-up: dose at baseline, 3.8 ± 1.9 g/week; at 6 months,
4.4 ± 2.2 g/week; at 12 months, 4.9 ± 2.4 g/week; at 18
months, 5.3 ± 2.3 g/week; and at 24 months, 5.9 ± 2.8 g/week
(Wilcoxon P = .002 for 6 months and P < .001 for the other
times).
Effect  on  bone  mineral  metabolism
Changes in parameters of bone mineral metabolism are
summarised in Table 2. PTH and alkaline phosphatase levels
decreased signiﬁcantly at sixth month. Patients with higher
initial levels of serum PTH levels had a more  marked reduction
in PTH, whereas patients in the lowest tercile had a moder-
ate change PTH (Fig. 1). A PTH decrease of >60% from baseline
value was seen in 11.9% of patients at 12 months, and in 23.9%
of patients at 24 months. PTH was reduced by >30% from base-
line in 42.4% of patients at 12 months and in 65.2% of patients
at 24 months.
Overall, serum calcium and phosphorus levels did not
change signiﬁcantly, nor did urinary excretion of calcium.
Phosphaturia and phosphate clearance decreased signiﬁ-
cantly at the end of follow-up (available measurements: n = 48
patients at baseline and n = 39 at 18 and 24 months).
To analyse the effect of initial calcium levels on changes
in PTH, we  classiﬁed patients by terciles according to their
500
450
400
350
300
250PT
H
 (p
g/m
L)
200
150
100
Baseline +6m +12m +18m +24m
PTH<227 pg/mL
PTH 227-299 pg/mL
PTH>299 pg/mL
P<.001
P<.001
P=.003 P<.001
P<.001
P=.009
P<.001
Fig. 1 – Changes in iPTH by terciles of initial iPTH. a P < .001;
b P = .003; c P = .009.
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Table 2 – Changes after treatment with paricalcitol in renal function and parameters of bone mineral metabolism in
blood and urine.
Baseline 6 m 12 m 18 m 24 m
Cr (mg/dL) 2.21 ± 0.93 2.29 ± 0.92 2.38 ± 0.97a 2.41 ± 0.95b 2.41 ± 1.05a
GFR-MDRD 36 ± 20 34 ± 18a 35 ± 23 33 ± 20b 33 ± 18a
iPTH (pg/mL) 288 ± 152 226 ± 184c 207 ± 120c 211 ± 140d 193 ± 119c
Reduc. PTH (median) (%) −24.1 −23.7 −29.7 −35.6
Patients with reduc. >30% from baseline PTH (%) 39 42.4 48.9 65.2
Alk. Phos. (IU/L) 92 ± 49 85 ± 35b 82 ± 38d 84 ± 44e 87 ± 41f
Ca (mg/dL) 9.7 ± 0.7 9.8 ± 0.6 9.6 ± 0.7 9.6 ± 0.6 9.6 ± 0.6
P (mg/dL) 3.4 ± 0.7 3.4 ± 0.9 3.4 ± 0.8 3.5 ± 0.7 3.6 ± 0.8
Calciuria (mg/day) 122 ± 99 125 ± 99 105 ± 82 120 ± 135 109 ± 91
Urinary Ca/Cr (%mg/mg) 10.5 ± 8.8 11.1 ± 9.1 9.4 ± 8.2 10.1 ± 12.5 9.6 ± 7.3
Frac. Exc. Ca (%) 1.81 ± 1.22 1.96 ± 1.64 1.80 ± 1.30 1.89 ± 1.21 1.95 ± 1.17
Phosphaturia (mg/day) 744 ± 305 704 ± 256 706 ± 316 667 ± 255g 629 ± 245h
ClP (mL/min) 16.3 ± 8.5 15.9 ± 7.7 15.4 ± 7.7 13.9 ± 6.7a 12.8 ± 6.7i
TRP (%) 64 ± 13 64 ± 13 63 ± 13 64 ± 15 63 ± 19
a P < .05.
b P = .005.
c P < .001.
d P = .001.
e P = .004.
f P = .007.
g P = .014.
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P=.006 P=.002
P=.035
P=.047 P=.026
P<.001 P<.001h P = .006.
i P = .002 (compared with baseline).
aseline serum calcium levels. We found that patients in
he lowest calcium tercile had higher baseline PTH values
nd that PTH decreased more  markedly than in the other
roups (Fig. 2). In patients who  began with baseline calcium
9.8 mg/dL (lowest tercile), serum calcium levels increased
rogressively but remained within normal range. In con-
rast, in patients who  began with serum calcium >10 mg/dL
highest tercile) calcium levels showed a signiﬁcant pro-
ressive decrease (Fig. 3). Paricalcitol dose was progressively
ncreased in all 3 calcium groups. This dose was increased
ore  rapidly in the group of patients with the lowest initial
alcium levels. At 24 months all groups were receiving sim-
lar doses of paricalcitol (Fig. 4). There were non-signiﬁcant
ifferences in renal function between the different calcium
erciles: Ca < 9.8 mg/dL, Cr 2.4 ± 0.9 mg/dL; Ca 9.8–10 mg/dL, Cr
.1 ± 0.7 mg/dL; Ca > 10 mg/dL, Cr 1.9 ± 1.1 mg/dL. Cinacalcet
400
350
300
250
PT
H
 (p
g/m
L)
200
150
100
Baseline +6m +12m +18m +24m
Ca<9.8 mg/dL
Ca 9.8-10 mg/dL
Ca>10 mg/dL
P=.002 P=.001
P=.012
P=.006
P=.011
P=.003
P=.032
ig. 2 – Changes in iPTH by initial calcium levels. a P = .003;
P = .011; c P = .006; d P = .032; e P = .012; f P = .002; g P = .001.
Baseline +6m +12m +18m +24m
Fig. 3 – Mean PTH values by group according to initial
a b c d ecalcium level. P = .006; P = .002; P = .035; P < .001;
P = .047; f P = .026.
was given to 6 of 21 patients (28.6%) in the lowest calcium
tertile, 2 of 24 (8.2%) in the middle tercile and 3 of 24 patients
(12.5%) in the highest tercile; and, the P value was not signiﬁ-
cant).
Patients were also classiﬁed according to their baseline
serum phosphorus levels. Patients from the lowest tercile
(P < 3.2 mg/dL) showed a signiﬁcant and progressive increase in
phosphorus levels, but levels remained within normal limits
(Fig. 5). In the other tertiles, the changes in serum phos-
phorus were not signiﬁcant. GFR was better in patients from
the lowest tertile of phosphate: 1st (lowest) tercile, serum Cr
1.5 ± 0.6 mg/dL; 2nd tercile, serum Cr 2.4 ± 1.1 mg/dL; 3rd ter-
cile, serum Cr 2.6 ± 0.6 mg/dL (P < .001). Mean baseline PTH
levels were different. There were differences in baseline PTH
levels among the different phosphorus tertiles: 1st tercile,
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Fig. 4 – Changes in paricalcitol dose and initial calcium
levels. a P = .004; b P = .007; c P = .008; d P = .017; e P = .04; f
P = .037; g P = .002; h P = .003.
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Fig. 5 – Mean PTH levels by group of initial calcium level. a
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Fig. 6 – Changes in iPTH by initial creatinine level. a
P < .001; b P = .03; c P = .005; d P = .024; e P = .011; f P = .002.
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Fig. 7 – Changes in PTH levels after paricalcitol at 6 monthsP = .015; P = .021; P = .001.
PTH 238 ± 100 pg/mL; 2nd tercile, PTH 252 ± 101 pg/mL; 3rd
tercile, PTH 362 ± 215 pg/mL (P < .001). In the 3 phosphorus
groups, PTH decreased gradually and at 24 months the PTH
values were similar for all Phosphate tertiles (154 ± 78 pg/mL;
186 ± 89 pg/mL; 189 ± 114 pg/mL).
When patients were classiﬁed according to baseline renal
function (terciles of creatinine), a more  signiﬁcant decrease
in PTH was observed in patients with worse renal function
(Fig. 6). There were no signiﬁcant changes in calcium or phos-
phorus levels in any group during the study.
The percent change in PTH from baseline to six months
correlated with baseline PTH level (r = −0.31; P = .016) and with
changes in calcium from baseline to six months (r = −0.33;
P = .011). This was observed even when patients without pre-
vious calcitriol treatment were analysed separately (Fig. 7).
The percent change in PTH at 12 months showed a correla-
tion with baseline PTH value (r = −0.47; P < .001) and with the
starting dose of paricalcitol (r = −0.27; P = .035), but not with
paricalcitol dose at 6 or 12 months or with changes in serum
calcium at 6 or 12 months. Paricalcitol dose at 12 months and
at 18 months showed a correlation with baseline PTH values
(r = 0.41 and P = .003, and r = 0.31 and P = .030, respectively).compared with baseline, in relation to changes in calcium.
Factors predictive of PTH response (percentage change
from baseline) were analysed using linear regression. The
following factors were introduced as independent variables:
paricalcitol dose at each time point, treatment with cinacalcet,
previous treatment with calcitriol, age, sex, months post-
transplant, baseline weight, calcium, phosphorus, baseline
PTH, and baseline creatinine/GFR-MDMR. At 6 months the
predictive factors were initial paricalcitol dose and prior
treatment with calcitriol (r = 0.37; P = .018). At 12 months the
predictive factors were baseline PTH and initial paricalcitol
dose (r = 0.63; P < .001). At 18 months the only predictive fac-
tor was baseline PTH level (r = 0.57; P < .001). We  looked for
predictors of paricalcitol dose at each time point, using lin-
ear regression, and found only baseline paricalcitol dose and
baseline PTH.When changes in calcium at 6 months were analysed using
linear regression, the predictive variables were baseline cal-
cium and phosphorus levels (r = 0.64; P < .001). At 12 months,
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he predictors were baseline calcium and paricalcitol dose at
2 months (r = 0.55; P < .001). At 18 months, the only predictor
as baseline calcium level.
Changes in alkaline phosphatase levels maintained a cor-
elation with PTH levels at 6 months (r = 0.29; P = .046), at 12
onths (r = 0.41; P = .003), at 18 months (r = 0.29; P = .048) and
t 24 months (r = 0.48; P = .003). There was no correlation with
aricalcitol dose or with changes in calcium or phosphorus
evels.
On linear regression analysis, changes in alkaline phos-
hatase values between baseline and six months were
igniﬁcantly related (r = 0.77; P < .001) with baseline alka-
ine phosphatase values (beta = −.73; P < .001), with previous
alcitriol treatment (beta = .32; P < .001), and with baseline
reatinine (beta = −.19; P = .0321). Between baseline and 12
onths, the predictors of change in alkaline phosphatase
r = 0.74; P < .001) were baseline alkaline phosphatase value
beta = −.67; P < .001), baseline calcium (beta = .25; P = .008),
revious treatment with calcitriol (beta = .25; P = .027), and
aseline creatinine (beta = −.19; P = .042), with no association
ith changes in PTH.
Comparison of patients treated with cyclosporine with
hose treated with tacrolimus did not show differences in
hanges in PTH, alkaline phosphatase, calcium, phosphorus,
xcretion of calcium or phosphorus, or dose of paricalcitol
sed. Likewise, there were no differences in these vari-
bles when comparing patients who received anticalcineurin
herapy or m-TOR  inhibitors as immunosuppression. Sex,
ge, time post-transplant, and diabetic status did not affect
mmunosuppression choice.
atients  previously  treated  with  calcitriol
ifteen patients (21.7%) had been receiving previous treatment
ith calcitriol, which was changed to paricalcitol. The ini-
ial dose conversion was 3.5 ± 1.8 g paricalcitol/g calcitriol
median, 3.4; range, 1–8 g paricalcitol/g calcitriol).
Paricalcitol dose was progressively increased in patients
reated with calcitriol, and these patients received higher
oses than other patients, as can be seen in Fig. 8 (Friedman < .001 for patients without calcitriol and P = .002 for patients
ith calcitriol). The most striking differences were between
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these groups at 12 months (Mann–Whitney P = .076) and 18
months (Mann–Whitney P = .019).
Changes in PTH, alkaline phosphatase, calcium, and phos-
phorus were similar, with similar ﬁnal levels in both groups of
patients (Fig. 9). There were no differences in urinary excretion
of calcium or phosphorus.
Patients  on  treatment  with  cinacalcet
Eleven patients (15.9%) were on treatment with cinacal-
cet when paricalcitol was introduced. The initial dose of
paricalcitol used in patients that were on cinacalcet treat-
ment was 3.5 ± 1.9 g/week. This dose was similar in patients
not taking cinacalcet (3.8 ± 1.9 g/week). The dose of pari-
calcitol was increased to the same extent in both groups
(Fig. 8). The dose of cinacalcet did not change throughout
follow-up: baseline, 53 ± 36 mg/day; 6 months, 60 ± 40 mg/day;
12 months, 60 ± 47 mg/day; 18 months, 71 ± 41 mg/day; 24
months, 71 ± 48 mg/day. In 7 patients there was no change in
cinacalcet dose at any point. In one patient it was stopped at
12 months. In one patient the daily dose increased by 30 mg
at 6 months. In the other 2 patients the daily dose increased
by 30 mg from 12 months to avoid further changes.
Changes in levels of calcium, phosphorus, PTH, and alka-
line phosphatase, and changes in the excretion of calcium and
phosphorus were parallel between patients with and with-
out cinacalcet (Fig. 10). Baseline levels of calcium, PTH, and
alkaline phosphatase were similar in both groups, as was the
dose of paricalcitol used at the 6-month intervals. Patients
with cinacalcet initially had slightly lower levels of phospho-
rus, although not signiﬁcantly, and had parallel changes to
patients without cinacalcet. Urinary excretion of calcium was
higher in patients with cinacalcet, with no signiﬁcant differ-
ences in its changes over the study period (Fig. 11).
DiscussionResidual secondary hyperparathyroidism is common in
renal transplant recipients. The factors associated with its
persistence10–12,15–17 are length of time on dialysis, severity of
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secondary hyperparathyroidism prior to transplant, need for
cinacalcet whilst on dialysis, degree of renal function achieved
by the graft, vitamin D receptor genotype, and post-transplant
circulating levels of vitamin D metabolites. Although sec-
ondary hyperparathyroidism has been associated with a
higher incidence of post-transplant bone fractures18 and with
loss of bone mass,19–21 there are no clear guidelines on the
treatment of residual post-transplant hyperparathyroidism.
The recommendations are general and are directed more
towards prevention and treatment of post-transplant osteope-
nia than speciﬁc goals of secondary hyperparathyroidism
treatment. Often, levels of PTH are maintained relatively high
for the degree of renal function achieved, if compared with
the recommended levels for patients with chronic renal failure
who  do not receive a transplant. Maintaining relatively high
levels of PTH could be advisable to obtain a good degree of bone
remodelling, counterbalancing the slowing effect of steroids
and anticalcineurin therapy on bone remodelling .22 However,
the maintenance of post-transplant secondary hyperparathy-
roidism even with hypercalcaemia does not guarantee a highly
remodelled bone; often a low degree of bone remodelling,
23or even an adynamic bone, is seen. The approach of not
starting active treatment unless there are complications could
explain why paricalcitol was started in our series in 29.1% of
patients with PTH of 250–349 pg/mL and in 23.6% of patients;3 5(4):363–373
with PTH > 350 pg/mL. The same can be observed in the series
presented by González,14 in which the average PTH level was
333 pg/mL at the time of starting paricalcitol.
Treatment of residual post-transplant hyperparathy-
roidism is based on the use of vitamin D derivatives and
cinacalcet. The use of Cinacalcet is widespread and recognised
in renal transplant patients with post-transplant hypercal-
caemia, especially during the ﬁrst post-transplant year.24,25
Often, when cinacalcet is stopped, new increases are seen
in PTH and calcium, requiring continued treatment for an
indeﬁnite time period.17,26 In some series of renal transplant
patients,27,28 supplementation with vitamin D derivatives
reduced PTH, although the reductions obtained were mod-
erate when initial PTH levels were very high. Increases in
serum calcium were also observed.27,28 The ideal levels of 25-
OH vitamin D are not well-established. A value of >30 ng/mL,
as in non-transplant patients, is recommended,27 although
levels above 20 ng/mL are probably sufﬁcient. Calcitriol has
been used in renal transplant patients, directed particularly
at the treatment of bone mass loss, with signiﬁcant reduc-
tions in PTH.19,29,30 Often, there is an associated increase in
calciuria9 and in serum calcium.31 Alfacalcidol also achieves
PTH reduction, but with an associated increase in serum
calcium and reduction of bone mass loss in the spine and
femur.32
Paricalcitol is a synthetic analogue of calcitriol. Parical-
citol has the advantage a reducing intestinal absorption of
calcium and phosphorus,33,34 which explains the lower inci-
dence of hypercalcaemia and hyperphosphataemia.35 There
is little experience with paricalcitol in renal transplants.
Amer13 studied paricalcitol as a treatment for post-transplant
secondary hyperparathyroidism: in a randomised trial, 51
patients received 1 g/day of paricalcitol from the third day
post-transplant, increasing to 2 g/day from 2 weeks until the
study end. With this dose, the prevalence of patients with
PTH >65 pg/mL was reduced to 29%, compared with 63% in
the placebo group. González14 performed a retrospective study
on 58 patients who were prescribed paricalcitol at a dose
of 1 g/day on alternate days, and observed an average PTH
decrease of 30–40%. PTH levels decreased by ≥30% in 55–76%
of patients. In our study, the population achieving a PTH reduc-
tion ≥30% at 12 months was 33.9%. As well as this milder
response in our series, we also observed a progressive increase
in paricalcitol dose used during the study, reaching double the
ﬁnal dose that was used in the study by González.14 The pop-
ulation of the study by Amer13 is not comparable to that of
our study as the patients had a short period of dialysis (11
months), lower initial PTH levels, and half of the patients had
a pre-emptive transplant.
In our study, the induced changes in PTH correlated
inversely with the changes in serum calcium at 6 months;
thereafter this correlation was lost. The main predictor of
reduction in PTH was the starting value of PTH. There was
no effect from the degree of renal function, initial phosphorus
level, or dose of paricalcitol used. This relationship was to be
expected, given that patients who start with higher PTH lev-
els will have quantitatively greater reductions to meet the ﬁnal
target PTH level, compared with those with lower PTH levels,
in whom a slight reduction will bring them into the desired
PTH range.
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Some studies have observed a relationship between par-
calcitol dose and degree of PTH reduction.1 In our study,
aricalcitol dose was directly related to the initial PTH level but
ot to the ﬁnal PTH level, and was inversely related to calcium
evels. This was probably because the paricalcitol doses used
t each point were adjusted by the nephrologist according to
nitial PTH levels and serum calcium levels, in most cases
iming for a moderate PTH target rather than trying to nor-
alise it completely. This was different to other prospective
ontrolled studies, which had stricter, more  uniform proto-
ols with increasing doses and more  ambitious PTH goals than
hose decided by the individual nephrologists in this study.
Patients that were previously on treatment with calcitriol
howed changes in PTH similar to patients without calcitriol,
ut required higher paricalcitol doses. Patients on treatment
ith cinacalcet experienced progressive decreases in PTH,
ith doses of paricalcitol similar to those of patients without
inacalcet. Combined treatment with paricalcitol and cinacal-
et was appealing from a pathophysiological point of view
n these patients. In transplant patients, cinacalcet has been
hown to be capable of resetting the set point of calcium36,37
nd increasing vitamin D receptors in parathyroid cells.38
n patients on haemodialysis, cinacalcet has been shown to
educe parathyroid gland size independently of the initial size.
his would suggest that it could be effective in cases of nodular
yperplasia.39 In the removed parathyroid glands of trans-
lant patients with hypercalcaemia, there is reduced density
f calcium sensing receptors and VDR only in glands with
odular hyperplasia, whereas this is almost normal in cases
f diffuse hyperplasia.40 The rate of parathyroid cell apopto-
is is much higher in glands with diffuse hyperplasia than in
odular hyperplasia, these rates being even higher than those
n patients on haemodialysis.40 This apoptosis, along with
ower proliferation, could explain the post-transplant reduc-
ion seen in the size of parathyroid glands.41,42
The number of vitamin D receptors and calcium sensing
eceptors in parathyroid cells is reduced in renal failure40,43
nd also immediately following renal transplant,43 with sub-
equent normalisation if there is no nodular hyperplasia.16,40
aricalcitol, unlike other vitamin D analogues, stimulates
he expression of calcium-sensing receptors and exerts an
ntiproliferative effect on parathyroid cells.44 Paricalcitol can
otentiate the effect of cinacalcet on parathyroid cells and pro-
ote a further decrease in PTH. In our short series of patients
e did not observe any differences in calcium level in patients
ith cinacalcet compared to those without. If there was an
ncrease in calcaemia, cinacalcet probably helped to control
his increase; thus allowing the use of higher paricalcitol doses
n cases of severe hyperparathyroidism to slow glandular pro-
uction of PTH. The dose of cinacalcet used did not change in
ost patients and in one patient cinacalcet was stopped. It is
ot yet known if the added reduction in PTH levels with par-
calcitol could facilitate the gradual withdrawal of cinacalcet
n some patients.
As was found in the other 2 series,13,14 overall, we  observed
o increase in calcium levels. This could be due in part to the
ephrologists’ caution with regard to increasing paricalcitol
oses, increasing them gradually according to the calcium
evels at each point (Fig. 3). In the series by Amer, the inci-
ence of hypercalcaemia was 20%. This forced them to stop(4):363–373 371
paricalcitol in 10% of patients. This hypercalcaemia could
probably be explained by the higher doses of paricalcitol used
(2 g/day), the concurrent administration of calcium sup-
plements along with paricalcitol, and the tendency towards
hypercalcaemia that is seen in the ﬁrst year post-transplant
in a signiﬁcant proportion of patients.
We  observed that changes in serum calcium depended on
the baseline calcium level: patients that began with lower lev-
els (Ca < 9.6 mg/dL) experienced a small increase in their levels,
but they remained within normal limits, whereas patients
with Ca > 9.9 mg/dL had no changes in their levels or even
showed mild decreases. In addition, a baseline calcium level
of <9.6 mg/dL was associated with higher baseline PTH levels
and a more  signiﬁcant PTH reduction than in patients with
a higher calcium level. Patients with lower baseline calcium
had slightly worse renal function, higher baseline PTH levels,
and higher paricalcitol doses, which could explain the increas-
ing trends in serum calcium. Patients belonging to the highest
tercile of calcium showed a reduction in calcium levels. This
was a consequence of reduced renal tubular reabsorption
and reduced bone resorption of calcium due to a decrease in
PTH.
Levels of alkaline phosphatase decreased progressively,
accompanying the PTH decrease, with a partial relationship
between changes in PTH and changes in alkaline phosphatase
values. The VITAL study also found this relationship, sug-
gesting that the decrease in alkaline phosphatase was a
consequence of not only PTH reduction, but also a direct sup-
pressive effect of paricalcitol on osteoblasts.1 In patients who
had had previous calcitriol treatment, alkaline phosphatase
levels were higher and decreased with paricalcitol in a par-
allel way to that of patients who had not previously received
calcitriol. These decreases were not observed to be related to
any factor, and other authors have found similarly.1 Immuno-
suppressor type did not show an effect on changes in alkaline
phosphatase, although the sample size of patients with m-
TOR inhibitors was too small to be able to compare with
patients on anticalcineurin therapy and draw deﬁnitive con-
clusions.
In summary, in this study we  describe the changes in PTH
in different subpopulations of long-term renal transplant
patients with secondary hyperparathyroidism treated with
paricalcitol, with a signiﬁcant reduction in PTH levels for all
PTH ranges. The initial PTH reduction was partially related
to an increase in serum calcium levels, especially in patients
with lower initial levels, although later this relationship was
lost. The response did not appear to depend on renal function
or initial calcium level. Patients who had previously received
calcitriol treatment required higher doses of paricalcitol than
those who had not. Patients on cinacalcet treatment showed
a good response on paricalcitol doses similar to those of
patients without cinacalcet. The use of paricalcitol appears
promising in renal transplant patients. A more  ambitious
treatment of residual secondary hyperparathyroidism could
be established, to see what effects it would have on bone
mineralisation, especially in long-term transplant patients.
In patients on cinacalcet treatment, a combined treatment
with paricalcitol could be used, directed at better control of
PTH, and potentially even allowing subsequent withdrawal
of cinacalcet. There remains to be studied the potential
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beneﬁcial effects of paricalcitol on bone mineralisation when
PTH levels are successfully reduced to suitable levels.
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